IceCure Medical (NASDAQ:ICCM - Get Free Report)'s stock had its "sell (e+)" rating restated by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.
A number of other research analysts have also weighed in on ICCM. Wall Street Zen lowered shares of IceCure Medical from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th. HC Wainwright raised their price objective on shares of IceCure Medical from $2.00 to $2.50 and gave the company a "buy" rating in a research note on Tuesday. Loop Capital set a $2.77 price objective on shares of IceCure Medical in a research note on Wednesday, August 13th. Zacks Research lowered shares of IceCure Medical from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Brookline Capital Management reaffirmed a "buy" rating on shares of IceCure Medical in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $2.64.
Get Our Latest Analysis on ICCM
IceCure Medical Stock Down 0.9%
IceCure Medical stock opened at $0.99 on Wednesday. The company has a quick ratio of 0.88, a current ratio of 1.18 and a debt-to-equity ratio of 0.02. IceCure Medical has a 12-month low of $0.51 and a 12-month high of $1.66. The firm's fifty day moving average is $0.98 and its 200 day moving average is $1.04. The company has a market capitalization of $68.09 million, a PE ratio of -6.20 and a beta of 0.31.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.12. IceCure Medical had a negative net margin of 317.62% and a negative return on equity of 136.96%. The firm had revenue of $0.66 million for the quarter, compared to the consensus estimate of $0.90 million. As a group, sell-side analysts predict that IceCure Medical will post -0.28 EPS for the current fiscal year.
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
